BP
BIIB icon

Ballentine Partners’s Biogen BIIB Stock Holding History

Ballentine Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
6,407
+57
+0.9% +$10.9K 0.02% 301
2026
Q1 		$1.16M Buy
6,350
+45
+0.7% +$8.29K 0.02% 320
2025
Q4 		$1.11M Buy
6,305
+364
+6% +$59.5K 0.02% 306
2025
Q3 		$832K Buy
5,941
+466
+9% +$63K 0.01% 367
2025
Q2 		$688K Buy
5,475
+1,651
+43% +$206K 0.01% 395
2025
Q1 		$523K Buy
3,824
+1,384
+57% +$198K 0.01% 434
2024
Q4 		$373K Buy
2,440
+911
+60% +$154K 0.01% 510
2024
Q3 		$296K Sell
1,529
-1,805
-54% -$378K 0.01% 596
2024
Q2 		$773K Buy
3,334
+1,667
+100% +$362K 0.01% 317
2024
Q1 		$359K Buy
1,667
+18
+1% +$4.22K 0.01% 487
2023
Q4 		$427K Buy
1,649
+121
+8% +$29.7K 0.01% 405
2023
Q3 		$393K Buy
1,528
+48
+3% +$12.8K 0.01% 367
2023
Q2 		$422K Buy
1,480
+59
+4% +$17.6K 0.01% 356
2023
Q1 		$395K Sell
1,421
-60
-4% -$16.6K 0.01% 349
2022
Q4 		$410K Sell
1,481
-1
-0.1% -$282 0.01% 316
2022
Q3 		$395K Buy
1,482
+307
+26% +$65.2K 0.01% 282
2022
Q2 		$241K Sell
1,175
-71
-6% -$14.5K 0.01% 364
2022
Q1 		$263K Sell
1,246
-77
-6% -$16.7K 0.01% 380
2021
Q4 		$317K Buy
1,323
+172
+15% +$44.2K 0.01% 356
2021
Q3 		$326K Sell
1,151
-162
-12% -$53.1K 0.01% 311
2021
Q2 		$454K Sell
1,313
-97
-7% -$29.4K 0.02% 249
2021
Q1 		$395K Sell
1,410
-39
-3% -$10.5K 0.01% 256
2020
Q4 		$355K Sell
1,449
-3,835
-73% -$989K 0.01% 253
2020
Q3 		$1.5M Sell
5,284
-1,651
-24% -$460K 0.07% 101
2020
Q2 		$1.85M Sell
6,935
-54
-0.8% -$16.2K 0.09% 90
2020
Q1 		$2.21M Buy
6,989
+58
+0.8% +$17.6K 0.13% 70
2019
Q4 		$2.06M Buy
6,931
+4,918
+244% +$1.36M 0.09% 88
2019
Q3 		$468K Buy
2,013
+48
+2% +$11.2K 0.02% 214
2019
Q2 		$460K Buy
1,965
+23
+1% +$5.31K 0.02% 223
2019
Q1 		$459K Sell
1,942
-7
-0.4% -$2.2K 0.02% 198
2018
Q4 		$587K Sell
1,949
-278
-12% -$88.7K 0.03% 176
2018
Q3 		$787K Sell
2,227
-1,877
-46% -$646K 0.04% 153
2018
Q2 		$1.19M Buy
4,104
+56
+1% +$15.7K 0.07% 95
2018
Q1 		$1.11M Buy
4,048
+2,171
+116% +$674K 0.06% 97
2017
Q4 		$598K Buy
1,877
+202
+12% +$64.8K 0.03% 170
2017
Q3 		$525K Sell
1,675
-20
-1% -$5.92K 0.03% 189
2017
Q2 		$480K Buy
1,695
+368
+28% +$97.3K 0.04% 202
2017
Q1 		$364K Sell
1,327
-446
-25% -$126K 0.03% 158
2016
Q4 		$495K Sell
1,773
-139
-7% -$41.2K 0.04% 115
2016
Q3 		$599K Sell
1,912
-53
-3% -$15.7K 0.05% 83
2016
Q2 		$476K Buy
1,965
+154
+9% +$40.6K 0.04% 116
2016
Q1 		$472K Buy
1,811
+507
+39% +$134K 0.04% 114
2015
Q4 		$400K Sell
1,304
-105
-7% -$30.2K 0.04% 112
2015
Q3 		$412K Buy
1,409
+208
+17% +$68.7K 0.04% 102
2015
Q2 		$485K Buy
1,201
+44
+4% +$17.7K 0.05% 93
2015
Q1 		$488K Sell
1,157
-10
-0.9% -$3.94K 0.05% 89
2014
Q4 		$396K Sell
1,167
-131
-10% -$42.4K 0.05% 107
2014
Q3 		$429K Buy
1,298
+111
+9% +$36.6K 0.05% 93
2014
Q2 		$374K Sell
1,187
-39
-3% -$11.7K 0.04% 99
2014
Q1 		$375K Buy
1,226
+56
+5% +$17.8K 0.04% 98
2013
Q4 		$327K Buy
1,170
+80
+7% +$20.7K 0.04% 111
2013
Q3 		$262K Buy
+1,090
New +$244K 0.03% 118

Other funds holding BIIB

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Ballentine Partners's BIIB Position: Q2 2026 in Review

Ballentine Partners increased its Biogen (BIIB) stake by 0.9% in Q2 2026, buying an estimated $10.9K and bringing the position to 6,407 shares worth $1.38M. The position accounts for 0.02% of the portfolio, ranked #301.

Ballentine Partners first reported a position in BIIB in Q3 2013 and has held it in 52 quarters since. The position peaked at $2.21M in Q1 2020. 135 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Ballentine Partners held 6,407 shares of Biogen worth $1.38M as of Q2 2026.
  • Ballentine Partners bought 57 Biogen shares in Q2 2026, an estimated $10.9K.
  • Biogen made up 0.02% of Ballentine Partners's portfolio in Q2 2026, its #301 holding.
  • Ballentine Partners first reported a position in Biogen in Q3 2013 and has held it in 52 quarters since.
  • Ballentine Partners's Biogen position peaked at $2.21M in Q1 2020.
  • 135 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.